Accueil/Actions/PCRX

PCRX

USD

Pacira BioSciences Inc. Common Stock

$24.450+0.100 (0.411%)

Prix en Temps Réel

Healthcare

Drug Manufacturers - Specialty & Generic

États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché

Fondamentaux de l'Entreprise

Statistiques de Trading

Métriques de Marché

Ouverture

$24.350

Haut

$24.590

Bas

$23.500

Volume

0.18M

Fondamentaux de l'Entreprise

Capitalisation Boursière

1.1B

Industrie

Drug Manufacturers - Specialty & Generic

Pays

United States

Statistiques de Trading

Volume Moyen

0.89M

Bourse

NMS

Devise

USD

Intervalle sur 52 Semaines

Bas $11.16Actuel $24.450Haut $29.61

Actualités Connexes

27 mai 2025 · 01:54

GlobeNewswire

Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX); and Treace Medical Concepts, Inc. (NASDAQ: TMCI)

PHILADELPHIA, May 26, 2025 (GLOBE NEWSWIRE) -- DoubleVerify Holdings, Inc. (NYSE:DV): If you have held DoubleVerify Holdings, Inc. (NYSE:DV) shares since prior to November 10, 2023, and would like to learn

Grabar Law Office Investigates Claims on Behalf of Shareholders of DoubleVerify Holdings, Inc. (NYSE: DV); NAPCO Securities Technologies, Inc. (NASDAQ: NSSC); Pacira Biosciences, Inc. (NASDAQ: PCRX); and Treace Medical Concepts, Inc. (NASDAQ: TMCI)

15 mai 2025 · 12:00

GlobeNewswire

Pacira BioSciences Presents New Data on the Effects of Clinical Immunogenicity on Locally Administered PCRX-201 in Patients with Moderate to Severe Osteoarthritis of the Knee

-- Early clinical data indicates that Pre-existing and treatment-induced anti-Ad5 neutralizing antibodies do not impact the safety and effectiveness of PCRX-201 – -- An oral presentation of the data to be featured at